Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Raymond Andersen

British Columbia Cancer Agency, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Essa Pharma Inc.

Disclosed Value
Listed Reason
Payment for services (e.g., consulting fees, honoraria, paid authorship)

There is a potential for a FCOI to exist between the SFI and the NIH research. Project results may be relevant to ESSA Pharma.

All of the above conditions function to ensure that the study is conducted and recorded in an objective and unbiased manner. The scheduled disclosure and reporting serve to safeguard the study against any potential bias and ensure that it is conducted with the highest ethical and scientific standards. The past COI Oversight Monitor's conclusion is that "it is the biological data that drives interest level of investors. There is nothing that Dr. Andersen can do to bias the outcome of the biological data. The structures of the compounds are unambiguous and there is no way to bias the chemical data to give a more favorable outcome."

Listed Research Project
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics

Once prostate cancer becomes castration-resistant there are no long-term or curative therapies that can be offered and the patient will succumb to his disease in a few years. There is mounting evidence supporting the concept that development of castration-resistant disease is causally related to molecular changes affecting the androgen receptor that include expression of constitutively active truncated splice variants that lack a C-terminus ligand-binding domain. Here we propose studies to reveal the mechanisms of antagonists of androgen receptor activation function-1 for further development of novel therapeutics that will delay or prevent hormonal progression to the terminal stage of prostate cancer.

Filed on March 24, 2017.

Tell us what you know about Raymond Andersen's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Raymond Andersen British Columbia Cancer Agency Conflict of Interest Essa Pharma Inc. >$600,000
Raymond Andersen Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. >$600,000
Raymond Andersen Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $150,000 - $199,999
Raymond Andersen Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. >$600,000
Raymond Andersen Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $150,000 - $199,999
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page